Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Breast Neoplasms
Clinical trial register · United States · industry-sponsored

Breast Neoplasms Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 13 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 25 Florida 20 Arizona 13 Colorado 12 Illinois 12
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Breast Neoplasms trials in the USA

30 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
NCT07811232Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
Advenchen Pharmaceuticals, LLC.
Phase 1/2
138
Texas
2026-09-01
Recruiting
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-22
Recruiting
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
NCT07505797Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms
iSono Health, Inc.
Observational
800
California, Texas
2025-12-16
Recruiting
BioNTech SE
Phase 3
558
Arkansas, California, Florida, Illinois, Kentucky, Maine, Maryland, Massachusetts
2025-10-30
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
Atavistik Bio, Inc
Phase 1
134
California, Florida, Massachusetts, Missouri, Texas
2025-07-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Colorado, Delaware, Florida, Kentucky, New Jersey
2025-07-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Maine
2025-06-30
Active, closed
Pfizer
Phase 1/2
74
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Active, closed
A Study of DM001 in Patients With Advanced Solid Tumors
NCT06475937Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1
128
Tennessee, Texas
2024-10-24
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2024-05-20
Active, closed
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05607004Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Atossa Therapeutics, Inc.
Phase 2
87
Arizona, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2023-02-14
Active, closed
Eli Lilly and Company
Phase 3
8,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-10-04
Recruiting
Stemline Therapeutics, Inc.
Phase 1/2
73
California, Illinois, Massachusetts, Michigan, Ohio, Oregon, Tennessee, Texas
2022-08-31
Active, closed
AstraZeneca
Phase 3
927
Arkansas, California, Connecticut, Indiana, Kentucky, Louisiana, Minnesota, Nevada
2021-10-25
Active, closed
Eli Lilly and Company
Phase 3
874
Arizona, California, Colorado, Florida, Hawaii, Illinois, Indiana, Kentucky
2021-10-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2021-06-18
Recruiting
GlaxoSmithKline
Phase 2
37
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, New Jersey
2021-04-16
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Pfizer
Phase 2
362
California, Connecticut, Massachusetts, Michigan, Tennessee, Texas
2020-09-23
Active, closed
Eisai Inc.
Phase 1
31
Florida, Massachusetts, Missouri, Nevada, Tennessee
2020-04-01
Active, closed
US Oncology Research
Phase 1/2
34
Texas
2017-11-29
Active, closed
Eli Lilly and Company
Phase 3
669
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2014-07-22
Active, closed
Eli Lilly and Company
Phase 1
198
Arkansas, California, Massachusetts, Minnesota, New York, North Carolina, Oregon, Pennsylvania
2014-03-10
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/breast-neoplasms

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 13 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies listing the condition Breast Neoplasms.

How many Breast Neoplasms trials are recruiting in the US?

15 of the 30 studies on this page are recruiting new participants as of the 13 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Neoplasms), 30 studies
PhaseStudiesRecruitingShare
Phase 310533.3%
Phase 16220%
Phase 26320%
Phase 1/25216.7%
Not applicable113.3%
Observational113.3%
Phase 2/3113.3%

Most active sponsors

Lead sponsors with the most studies (Breast Neoplasms)
Lead sponsorStudiesRecruiting
Eli Lilly and Company84
Merck Sharp & Dohme LLC65
Pfizer20
Advenchen Pharmaceuticals, LLC.10
AstraZeneca10
Atavistik Bio, Inc10
Atossa Therapeutics, Inc.10
BioNTech SE11
Bristol-Myers Squibb11
Eisai Inc.10

Top states

Top states (Breast Neoplasms), by number of studies with a site there
StateStudies
California25
Florida20
Arizona13
Colorado12
Illinois12
Massachusetts12
Georgia10
Texas8
Arkansas7
Connecticut7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.